These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 28537985)

  • 21. Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease.
    Caminiti SP; Presotto L; Baroncini D; Garibotto V; Moresco RM; Gianolli L; Volonté MA; Antonini A; Perani D
    Neuroimage Clin; 2017; 14():734-740. PubMed ID: 28409113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuromelanin-sensitive MRI of the substantia nigra: An imaging biomarker to differentiate essential tremor from tremor-dominant Parkinson's disease.
    Wang J; Huang Z; Li Y; Ye F; Wang C; Zhang Y; Cheng X; Fei G; Liu K; Zeng M; Zhong C; Jin L
    Parkinsonism Relat Disord; 2019 Jan; 58():3-8. PubMed ID: 30037690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nigrostriatal dopamine-independent resting-state functional networks in Parkinson's disease.
    Ham JH; Cha J; Lee JJ; Baek GM; Sunwoo MK; Hong JY; Shin NY; Sohn YH; Lee JM; Lee PH
    Neuroimage; 2015 Oct; 119():296-304. PubMed ID: 26143204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
    Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
    Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of striatal silent lacunar infarction on the substantia nigra and movement disorders in Parkinson's disease: A follow-up study.
    Zhang G; Zhang C; Zhang Y; Wang Y; Nie K; Zhang B; Xie H; Lu J; Wang L
    Parkinsonism Relat Disord; 2017 Oct; 43():33-37. PubMed ID: 28688982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imaging the Substantia Nigra in Parkinson Disease and Other Parkinsonian Syndromes.
    Bae YJ; Kim JM; Sohn CH; Choi JH; Choi BS; Song YS; Nam Y; Cho SJ; Jeon B; Kim JH
    Radiology; 2021 Aug; 300(2):260-278. PubMed ID: 34100679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study.
    Rossi C; Frosini D; Volterrani D; De Feo P; Unti E; Nicoletti V; Kiferle L; Bonuccelli U; Ceravolo R
    Eur J Neurol; 2010 Apr; 17(4):626-30. PubMed ID: 20050904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The diagnostic value of SNpc using NM-MRI in Parkinson's disease: meta-analysis.
    Wang X; Zhang Y; Zhu C; Li G; Kang J; Chen F; Yang L
    Neurol Sci; 2019 Dec; 40(12):2479-2489. PubMed ID: 31392640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of SPECT imaging of the dopaminergic system in translational research on Parkinson's disease.
    Suwijn SR; de Bruin K; de Bie RM; Booij J
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S184-6. PubMed ID: 24262177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications.
    Kuriakose R; Stoessl AJ
    Prog Brain Res; 2010; 184():177-92. PubMed ID: 20887875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts.
    Kraemmer J; Kovacs GG; Perju-Dumbrava L; Pirker S; Traub-Weidinger T; Pirker W
    Mov Disord; 2014 Dec; 29(14):1767-73. PubMed ID: 25048738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences.
    Thobois S; Jahanshahi M; Pinto S; Frackowiak R; Limousin-Dowsey P
    Neuroimage; 2004 Sep; 23(1):1-16. PubMed ID: 15325346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopaminergic function and progression of Parkinson's disease: PET findings.
    Biju G; de la Fuente-Fernández R
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S38-40. PubMed ID: 20123555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of substantia nigra hyperintensity on 7 Tesla MRI of Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Kim JM; Jeong HJ; Bae YJ; Park SY; Kim E; Kang SY; Oh ES; Kim KJ; Jeon B; Kim SE; Cho ZH; Kim YB
    Parkinsonism Relat Disord; 2016 May; 26():47-54. PubMed ID: 26951846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Presynaptic nigro-striatal function in a group of Alzheimer's disease patients with parkinsonism: evidence from a dopamine transporter imaging study.
    Ceravolo R; Volterrani D; Gambaccini G; Bernardini S; Rossi C; Logi C; Tognoni G; Manca G; Mariani G; Bonuccelli U; Murri L
    J Neural Transm (Vienna); 2004 Aug; 111(8):1065-73. PubMed ID: 15254794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Substantia nigra neuromelanin-MR imaging differentiates essential tremor from Parkinson's disease.
    Reimão S; Pita Lobo P; Neutel D; Guedes LC; Coelho M; Rosa MM; Azevedo P; Ferreira J; Abreu D; Gonçalves N; Nunes RG; Campos J; Ferreira JJ
    Mov Disord; 2015 Jun; 30(7):953-9. PubMed ID: 25758364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 7 Tesla magnetic resonance imaging: a closer look at substantia nigra anatomy in Parkinson's disease.
    Lehéricy S; Bardinet E; Poupon C; Vidailhet M; François C
    Mov Disord; 2014 Nov; 29(13):1574-81. PubMed ID: 25308960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence for Dopamine Abnormalities in the Substantia Nigra in Cocaine Addiction Revealed by Neuromelanin-Sensitive MRI.
    Cassidy CM; Carpenter KM; Konova AB; Cheung V; Grassetti A; Zecca L; Abi-Dargham A; Martinez D; Horga G
    Am J Psychiatry; 2020 Nov; 177(11):1038-1047. PubMed ID: 32854531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Usefulness of transcranial sonography in Parkinson's disease. A comparative study using 123I-FP-CIT SPECT].
    Hernández Vara J; Rubiera del Fueyo M; Lorenzo Bosquet C; Castell Conesa J; Molina Cateriano CA; Rodríguez FM
    Med Clin (Barc); 2008 Sep; 131(8):285-9. PubMed ID: 18803921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diffusion tensor imaging of the substantia nigra in Parkinson's disease revisited.
    Langley J; Huddleston DE; Merritt M; Chen X; McMurray R; Silver M; Factor SA; Hu X
    Hum Brain Mapp; 2016 Jul; 37(7):2547-56. PubMed ID: 27029026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.